Stock Update (NYSE:PFE): HemoShear Therapeutics Announces Next Stage of Safety Collaboration with Pfizer Inc.

[PR Newswire] – CHARLOTTESVILLE, Va., Jan. 11, 2016 /PRNewswire/ — HemoShear Therapeutics, LLC (HemoShear), a privately held discovery-stage biotechnology company, today announced that it would be initiating the next stage of a multi-year collaboration with Pfizer Inc. (PFE). Under the terms of the agreement, which combines the scientific and technical expertise of both companies, HemoShear will leverage its proprietary discovery platform, REVEAL-Tx™, with the aim of developing a predictive model for preclinical drug-induced vascular injury (DIVI). Financial terms were not disclosed. The initial stage of the collaboration between HemoShear and Pfizer was designed to assess the repeatability of vascular toxicities of a specifically chosen set of drugs in HemoShear’s REVEAL-Tx™ platform. In this next stage, the companies will use HemoShear’s platform to assess a large number of compounds with the aim of building a predictive computational model that would be used for evaluation of vascular safety of Pfizer drug compounds before entering pre-clinical stages of development. Read more on this. Pfizer Inc. (PFE) , with a current value of $191.38B, opened at $31.15. Looking at today’s market, PFE one day range is $30.76 to $31.19 with a trailing 52-week range being $28.47 to $36.46. Pfizer (PFE) shares are currently priced at 14.22x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -3.59x earnings multiple for the same period. And for passive income investors, the company pays shareholders $1.20 per share annually in dividends, yielding 3.72%. Consensus earnings for the current quarter by the 16 sell-side analysts covering the stock is an estimate of $0.52 per share, which would be $0.02 worse than the year-ago quarter and a $0.01 sequential increase. Furthermore, our analysis shows the full-year EPS estimate to be $2.18, which would be a $0.08 setback when compared to the last year’s annual results. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $13.54 Billion. If realized, that would be a 3.28% increase over the year-ago quarter. Recently, Sun Trust Rbsn Humphrey upgraded PFE from Reduce to Neutral (Nov 25, 2015). Previously, Morgan Stanley upgraded PFE from Equal-Weight to Overweight. The average price target for PFE shares is $40.56, which is 30.21% above where the stock opened this morning. See more in (NYSE:PFE) Similar Articles: Company Update: Pfizer Inc (NYSE:PFE) – Pfizer Announces Collaboration with GSK on Next-Generation Design of Portable, Continuous, Miniature and Modular (PCMM) Oral Solid Dose Development and Manufacturing Units Market Update: Pfizer Inc (NYSE:PFE) – Pfizer’s Phase 2 Study Demonstrates Safety, Tolerability and Immunogenicity of TRUMENBA® When Coadministered with Meningococcal A, C, Y and W-135 Polysaccharide Conjugate (MCV4) and Tetanus, Diphtheria and Pertussis (Tdap) Vaccines in Adole Company Update: Pfizer Inc (NYSE:PFE) – Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder